|
Release date as of 2024-10-31. Data on page is subject to change. |
|
|
Overall Morningstar Rating™
|
What is this?
|
|
|
As of 2024-10-31 |
|
Out of 160 Health Funds
|
|
|
|
|
|
Total Fund Assets ($ Mil) |
177.45 |
|
|
|
Investment Objective & Strategy |
|
The investment seeks long-term growth of capital.
|
|
The fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in securities of issuers engaged primarily in health care-related industries, and in derivatives and other instruments that have economic characteristics similar to such securities. It invests primarily in equity securities, including common and preferred stock, and depositary receipts. The fund may invest in securities of foreign issuers including up to 20% of its net assets in securities of issuers located in emerging markets countries, i.e., those that are in the early stages of their industrial cycles. |
|
|
Morningstar Category: Health |
|
Health portfolios focus on the medical and health-care industries. Most invest in a range of companies, buying everything from pharmaceutical and medical-device makers to HMOs, hospitals, and nursing homes. A few portfolios concentrate on just one industry segment, such as service providers or biotechnology firms.
|
|
|
Sector Funds: Funds that invest exclusively in one sector or industry involve risks due to the lack of industry diversification and expose the investor to increased industry-specific risks. |
|
|
% of Net Assets |
|
U.S. Stocks |
90.0 |
|
Non-U.S. Stocks |
7.9 |
|
Bonds |
0.0 |
|
Cash |
2.1 |
|
Other |
0.0 |
|
|
|
Data through 2024-09-30 |
|
|
|
|
Morningstar Equity Sectors |
|
|
|
% of Stocks |
|
Cyclical |
1.29 |
|
Basic Materials |
0.00 |
|
Consumer Cyclical |
0.00 |
|
Financial Services |
0.00 |
|
Real Estate |
1.29 |
|
|
|
|
Sensitive |
0.00 |
|
Communication Services |
0.00 |
|
Energy |
0.00 |
|
Industrials |
0.00 |
|
Technology |
0.00 |
|
|
|
|
Defensive |
98.71 |
|
Consumer Defensive |
0.00 |
|
Healthcare |
98.71 |
|
Utilities |
0.00 |
|
Data through 2024-09-30 |
|
|
Total Number of Stock Holdings |
81 |
Total Number of Bond Holdings |
0 |
% of Net Assets in Top 10 Holdings |
48.16 |
|
|
Turnover % |
(as of 2023-12-31) |
57.00 |
30 Day SEC Yield % |
--- |
|
|
Sector |
P/E |
% of Net Assets
|
|
|
|
|
|
|
Eli Lilly and Co |
|
89.41 |
9.39 |
|
Boston Scientific Corp |
|
69.44 |
6.60 |
|
UnitedHealth Group Inc |
|
36.70 |
5.38 |
|
Intuitive Surgical Inc |
|
81.00 |
4.35 |
|
Danaher Corp |
|
46.35 |
4.32 |
|
|
Thermo Fisher Scientific Inc |
|
34.25 |
3.79 |
|
Vertex Pharmaceuticals Inc |
|
--- |
3.77 |
|
AstraZeneca PLC ADR |
|
--- |
3.63 |
|
Regeneron Pharmaceuticals Inc |
|
20.73 |
3.50 |
|
Elevance Health Inc |
|
14.77 |
3.43 |
|
|
|
|
|
|
|
|
Emerging Markets, Foreign Securities, Loss of Money, Not FDIC Insured, Active Management, Market/Market Volatility, Depositary Receipts, Equity Securities, Industry and Sector Investing, Preferred Stocks, Derivatives, Small Cap, Mid-Cap |
|
Show Risk Definitions |
|
|
Inception Date: 1997-05-21 |
|
Justin J. Livengood (2020-12-18) |
|
Mr. Livengood has been a Vice President of OppenheimerFunds since May 2006 and a Senior Portfolio Manager since January 2014. He was a Senior Research Analyst from May 2006 to January 2014, responsible for the health care, energy and financial services sectors for mid- and small-cap growth accounts. Before joining OppenheimerFunds in May 2006, Mr. Livengood was a vice president and fund analyst with Merrill Lynch Investment Managers. During his tenure at Merrill Lynch he also worked as an investment banking analyst in the Global Media Group and as an associate with Merrill Lynch Ventures. |
|
|
|
|
|
|
|
|
|
© Copyright 2024 Morningstar, Inc. All rights reserved. Morningstar, the Morningstar logo, Morningstar.com, Morningstar Tools are either trademark or service marks of Morningstar, Inc. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or any losses arising from any use of information. Past performance is no guarantee of future performance. |
|
Past performance is no guarantee of future results.
Returns will vary and shares may be worth more or less than their original cost when sold.
|
|